JP2016511823A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016511823A5 JP2016511823A5 JP2015553864A JP2015553864A JP2016511823A5 JP 2016511823 A5 JP2016511823 A5 JP 2016511823A5 JP 2015553864 A JP2015553864 A JP 2015553864A JP 2015553864 A JP2015553864 A JP 2015553864A JP 2016511823 A5 JP2016511823 A5 JP 2016511823A5
- Authority
- JP
- Japan
- Prior art keywords
- kininogen
- intact
- value
- cut
- pkal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361754607P | 2013-01-20 | 2013-01-20 | |
| US61/754,607 | 2013-01-20 | ||
| PCT/US2014/012107 WO2014113712A1 (en) | 2013-01-20 | 2014-01-17 | Evaluation and treatment of bradykinin-mediated disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018221155A Division JP6772237B2 (ja) | 2013-01-20 | 2018-11-27 | ブラジキニン媒介障害の評価および治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016511823A JP2016511823A (ja) | 2016-04-21 |
| JP2016511823A5 true JP2016511823A5 (https=) | 2017-02-23 |
| JP6444315B2 JP6444315B2 (ja) | 2018-12-26 |
Family
ID=51210106
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015553864A Active JP6444315B2 (ja) | 2013-01-20 | 2014-01-17 | ブラジキニン媒介障害の評価および治療 |
| JP2018221155A Active JP6772237B2 (ja) | 2013-01-20 | 2018-11-27 | ブラジキニン媒介障害の評価および治療 |
| JP2020164435A Pending JP2021008483A (ja) | 2013-01-20 | 2020-09-30 | ブラジキニン媒介障害の評価および治療 |
| JP2022029441A Active JP7496380B2 (ja) | 2013-01-20 | 2022-02-28 | ブラジキニン媒介障害の評価および治療 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018221155A Active JP6772237B2 (ja) | 2013-01-20 | 2018-11-27 | ブラジキニン媒介障害の評価および治療 |
| JP2020164435A Pending JP2021008483A (ja) | 2013-01-20 | 2020-09-30 | ブラジキニン媒介障害の評価および治療 |
| JP2022029441A Active JP7496380B2 (ja) | 2013-01-20 | 2022-02-28 | ブラジキニン媒介障害の評価および治療 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11156612B2 (https=) |
| EP (3) | EP2948479B1 (https=) |
| JP (4) | JP6444315B2 (https=) |
| KR (3) | KR102203880B1 (https=) |
| CN (2) | CN105073778B (https=) |
| AU (4) | AU2014207420B2 (https=) |
| CA (2) | CA2897336C (https=) |
| CY (1) | CY1122164T1 (https=) |
| DK (1) | DK2948479T3 (https=) |
| ES (1) | ES2692408T3 (https=) |
| HR (1) | HRP20181734T1 (https=) |
| HU (1) | HUE041332T2 (https=) |
| IL (2) | IL273688B2 (https=) |
| LT (1) | LT2948479T (https=) |
| PL (1) | PL2948479T3 (https=) |
| PT (1) | PT2948479T (https=) |
| RS (1) | RS57890B1 (https=) |
| SI (1) | SI2948479T1 (https=) |
| SM (1) | SMT201800563T1 (https=) |
| TR (1) | TR201815856T4 (https=) |
| WO (1) | WO2014113712A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3459564B1 (en) | 2010-01-06 | 2021-10-27 | Takeda Pharmaceutical Company Limited | Plasma kallikrein binding proteins |
| CA2823776A1 (en) | 2011-01-06 | 2012-07-12 | Dyax Corp. | Plasma kallikrein binding proteins |
| WO2014113712A1 (en) | 2013-01-20 | 2014-07-24 | Dyax Corp. | Evaluation and treatment of bradykinin-mediated disorders |
| WO2014152232A2 (en) | 2013-03-15 | 2014-09-25 | Dyax Corp. | Anti-plasma kallikrein antibodies |
| TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
| CA2927695C (en) | 2013-10-21 | 2022-03-01 | Dyax Corp. | Diagnosis and treatment of autoimmune diseases |
| JP6757252B2 (ja) | 2013-10-21 | 2020-09-16 | ダイアックス コーポレーション | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
| AU2015209481C1 (en) | 2014-01-21 | 2020-10-29 | Takeda Pharmaceutical Company Limited | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema |
| IL295414B2 (en) | 2014-03-27 | 2026-02-01 | Takeda Pharmaceuticals Co | Compositions and methods for treating macular edema due to diabetes |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| BR112017020864A2 (en) * | 2015-03-30 | 2018-07-10 | Dyax Corp. | plasma kallikrein inhibitors and their uses for the prevention of hereditary angioedema attack |
| KR20240133761A (ko) * | 2015-10-19 | 2024-09-04 | 다케다 파머수티컬 컴패니 리미티드 | 절단된 고분자량 키니노겐의 검출을 위한 면역검정법 |
| AU2016366557B2 (en) * | 2015-12-11 | 2024-01-25 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| EP3390439B1 (en) * | 2015-12-15 | 2025-03-12 | Takeda Pharmaceutical Company Limited | Peptide quantitation assay for differentiating full-length high molecular weight kininogen (hmwk) and cleaved hmwk |
| IL263235B (en) | 2016-05-31 | 2022-07-01 | Kalvista Pharmaceuticals Ltd | History of pyrazoles as plasma kallikrein inhibitors |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| AU2017325986B2 (en) * | 2016-09-16 | 2023-12-14 | Takeda Pharmaceutical Company Limited | Metabolite biomarkers for diseases associated with the contact activation system |
| KR102806918B1 (ko) * | 2016-09-16 | 2025-05-14 | 다케다 파머수티컬 컴패니 리미티드 | 접촉 활성화 시스템과 연관된 질환을 위한 단백질 바이오마커 |
| HUE057912T2 (hu) | 2017-11-29 | 2022-06-28 | Kalvista Pharmaceuticals Ltd | Plazma kallikrein inhibitort tartalmazó dózisformák |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| US20200407771A1 (en) * | 2018-02-22 | 2020-12-31 | The Regents Of The University Of California | Threshold-stimulated plasma kallikrein activity as a biomarker for diagnosis of bradykinin-mediated angioedema |
| WO2021028645A1 (en) | 2019-08-09 | 2021-02-18 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| US12528880B2 (en) | 2020-01-13 | 2026-01-20 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack |
| JP2023521667A (ja) * | 2020-04-04 | 2023-05-25 | 武田薬品工業株式会社 | 血漿カリクレイン阻害剤及び急性呼吸窮迫症候群を処置するためのその使用 |
| CN113777331A (zh) * | 2020-06-09 | 2021-12-10 | 张曼 | 尿液激肽原-1及其多肽片段在烧伤中的应用 |
| EP4548103A2 (en) * | 2022-06-30 | 2025-05-07 | Takeda Pharmaceutical Company Limited | Protein biomarkers for lanadelumab treatment |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1312564C (en) | 1985-07-12 | 1993-01-12 | Robert W. Colman | Monoclonal antibodies to human plasma prekallikrein and methods of preparing and using same |
| US5047323A (en) | 1986-01-22 | 1991-09-10 | Temple University Of The Commonwealth System Of Higher Education | Method for detecting human kininogen using monoclonal antibodies thereto |
| US4908431A (en) * | 1986-01-22 | 1990-03-13 | Temple University-Of The Commonwealth System Of Higher Education | Monoclonal antibodies to human kininogen and methods of preparing same |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| KR960009766B1 (ko) | 1986-09-10 | 1996-07-24 | 니혼 소오끼 세이야꾸 가부시기가이샤 | 생리 활성물질 측정법 |
| US4882272A (en) * | 1986-10-01 | 1989-11-21 | Temple University - Of The Commonwealth System Of Higher Education | High molecular weight kininogen assay |
| US5025796A (en) | 1988-12-01 | 1991-06-25 | The United States Of America As Represented By The Department Of Health And Human Services | Apparatus and methods for determining in vivo response to thermal stimulation in in an unrestrained subject |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| AU2548992A (en) * | 1991-08-13 | 1993-03-16 | Temple University - Of The Commonwealth System Of Higher Education | Modulation of blood pressure and inhibition of platelet activation with kininogen fragment |
| PT739355E (pt) | 1994-01-11 | 2005-01-31 | Dyax Corp | Proteinas de 'dominio de kunitz' inibidoras de calicreina e seus analogos |
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| JPH1084995A (ja) | 1996-09-12 | 1998-04-07 | Nippon Zoki Pharmaceut Co Ltd | 血液凝固第ｘｉｉ因子活性化法 |
| US5789261A (en) | 1996-10-30 | 1998-08-04 | Temple University Of The Commonwealth System Of Higher Education | Solid phase immunoassay |
| US6242210B1 (en) | 1997-05-20 | 2001-06-05 | Actinova Limited | Treatment of bacterial infections |
| JP4346798B2 (ja) | 1999-08-19 | 2009-10-21 | 協和メデックス株式会社 | Ｈｃｖコア抗原の検出または定量方法およびそれに用いる検出または定量試薬。 |
| US6994852B1 (en) * | 1999-11-12 | 2006-02-07 | Temple University-Of The Commonwealth System Of Higher Education | Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5 |
| US7067713B2 (en) | 2000-01-31 | 2006-06-27 | Pharming Intellectual Property B.V. | C1 Inhibitor produced in the milk of transgenic non-human mammals |
| US7678541B2 (en) | 2000-11-21 | 2010-03-16 | Hologic, Inc. | Methods and compositions for the detection of a nucleic acid using a non-invasive cleavage reaction |
| JP2002221519A (ja) | 2001-01-29 | 2002-08-09 | Sysmex Corp | 抗凝固剤およびそれを用いた抗凝固剤処理方法 |
| US20040152633A1 (en) | 2001-05-31 | 2004-08-05 | Jorgensen Marianne Ulrich | Kunitz-type sequences and polypeptides |
| US6913900B2 (en) | 2001-08-29 | 2005-07-05 | Nippon Zoki Pharmaceutical Co., Ltd. | Plasma prekallikrein activation and kallikrein production assay |
| WO2003103475A2 (en) | 2002-06-07 | 2003-12-18 | Dyax Corp. | Prevention and reduction of blood loss |
| WO2004005934A2 (en) * | 2002-07-04 | 2004-01-15 | Oxford Glycosciences (Uk) Ltd | Toxicity markers |
| US20070003552A1 (en) | 2002-07-09 | 2007-01-04 | Gebbink Martijn F B | Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation |
| EP1598428A1 (en) | 2004-05-18 | 2005-11-23 | Georg Dewald | Methods and kits to detect Hereditary angioedema type III |
| US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| SI1981519T1 (en) | 2005-12-29 | 2018-05-31 | Dyax Corp. | INHIBITION PROTEAZE |
| US7276480B1 (en) | 2005-12-30 | 2007-10-02 | Dyax Corp. | Prevention and reduction of blood loss |
| JP5322935B2 (ja) | 2006-07-31 | 2013-10-23 | アクティベサイト ファーマシューティカルズ インコーポレイティッド | 血漿カリクレインの阻害薬 |
| CA2696208A1 (en) | 2007-08-21 | 2009-02-26 | Genzyme Corporation | Treatment with kallikrein inhibitors |
| EP2216651A4 (en) * | 2007-10-18 | 2010-12-01 | Miyazaki Prefectural Ind Suppo | BIOMARKERS FOR THE DIAGNOSIS OF LIVER DISEASE |
| AU2008315938B2 (en) | 2007-10-22 | 2014-11-27 | Georg Dewald | Disorders of vasoregulation and methods of diagnosing them |
| US20110212104A1 (en) | 2008-11-03 | 2011-09-01 | Schering Corporation | Inflammatory bowel disease biomarkers and related methods of treatment |
| EP2369930A4 (en) | 2008-12-02 | 2012-10-03 | Joslin Diabetes Ct | METHOD OF REDUCING BLOOD PRESSURE USING PLASMATIC KALLICREIN INHIBITORS |
| AU2013205086A1 (en) * | 2009-01-06 | 2013-05-16 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
| FR2942233B1 (fr) | 2009-02-19 | 2015-03-13 | Lfb Biotechnologies | Moyens pour la purification d'une proteine du plasma sanguin, et procedes pour sa mise en oeuvre |
| EP2512466A4 (en) | 2009-12-18 | 2013-07-03 | Activesite Pharmaceuticals Inc | PRODRUGS OF INHIBITORS OF PLASMATIC KALLICREIN |
| US9206123B2 (en) | 2009-12-18 | 2015-12-08 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| EP3459564B1 (en) | 2010-01-06 | 2021-10-27 | Takeda Pharmaceutical Company Limited | Plasma kallikrein binding proteins |
| WO2012009447A2 (en) | 2010-07-13 | 2012-01-19 | University Of Rochester | THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF |
| US10299714B2 (en) | 2010-12-02 | 2019-05-28 | Becton, Dickinson And Company | Blood collection devices containing blood stabilization agent including variegin or analog thereof and/or a polysulfated disaccharide |
| CA2823776A1 (en) | 2011-01-06 | 2012-07-12 | Dyax Corp. | Plasma kallikrein binding proteins |
| WO2012170947A2 (en) | 2011-06-10 | 2012-12-13 | Isis Pharmaceuticals, Inc. | Methods for modulating factor 12 expression |
| US9315811B2 (en) | 2011-06-10 | 2016-04-19 | Ionis Pharmaceuticals, Inc. | Methods for modulating kallikrein (KLKB1) expression |
| WO2014113712A1 (en) | 2013-01-20 | 2014-07-24 | Dyax Corp. | Evaluation and treatment of bradykinin-mediated disorders |
| JP2016505159A (ja) | 2013-02-01 | 2016-02-18 | ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ | 接触経路抑制添加剤を含む血液採集装置 |
| CA2927695C (en) * | 2013-10-21 | 2022-03-01 | Dyax Corp. | Diagnosis and treatment of autoimmune diseases |
| JP6757252B2 (ja) | 2013-10-21 | 2020-09-16 | ダイアックス コーポレーション | 血漿カリクレイン系バイオマーカーを決定するためのアッセイ |
| AU2015209481C1 (en) | 2014-01-21 | 2020-10-29 | Takeda Pharmaceutical Company Limited | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema |
| KR20240133761A (ko) | 2015-10-19 | 2024-09-04 | 다케다 파머수티컬 컴패니 리미티드 | 절단된 고분자량 키니노겐의 검출을 위한 면역검정법 |
-
2014
- 2014-01-17 WO PCT/US2014/012107 patent/WO2014113712A1/en not_active Ceased
- 2014-01-17 LT LTEP14740444.6T patent/LT2948479T/lt unknown
- 2014-01-17 IL IL273688A patent/IL273688B2/en unknown
- 2014-01-17 TR TR2018/15856T patent/TR201815856T4/tr unknown
- 2014-01-17 HU HUE14740444A patent/HUE041332T2/hu unknown
- 2014-01-17 CN CN201480005158.6A patent/CN105073778B/zh active Active
- 2014-01-17 US US14/761,690 patent/US11156612B2/en active Active
- 2014-01-17 EP EP14740444.6A patent/EP2948479B1/en active Active
- 2014-01-17 CA CA2897336A patent/CA2897336C/en active Active
- 2014-01-17 PT PT14740444T patent/PT2948479T/pt unknown
- 2014-01-17 PL PL14740444T patent/PL2948479T3/pl unknown
- 2014-01-17 ES ES14740444.6T patent/ES2692408T3/es active Active
- 2014-01-17 EP EP18186356.4A patent/EP3456744B1/en active Active
- 2014-01-17 CA CA3209608A patent/CA3209608A1/en active Pending
- 2014-01-17 EP EP23164279.4A patent/EP4234583A3/en active Pending
- 2014-01-17 SI SI201430933T patent/SI2948479T1/sl unknown
- 2014-01-17 AU AU2014207420A patent/AU2014207420B2/en active Active
- 2014-01-17 KR KR1020157022389A patent/KR102203880B1/ko active Active
- 2014-01-17 RS RS20181235A patent/RS57890B1/sr unknown
- 2014-01-17 SM SM20180563T patent/SMT201800563T1/it unknown
- 2014-01-17 CN CN201911415224.8A patent/CN111044725B/zh active Active
- 2014-01-17 HR HRP20181734TT patent/HRP20181734T1/hr unknown
- 2014-01-17 DK DK14740444.6T patent/DK2948479T3/en active
- 2014-01-17 KR KR1020217000831A patent/KR102381478B1/ko active Active
- 2014-01-17 KR KR1020227010217A patent/KR102523810B1/ko active Active
- 2014-01-17 JP JP2015553864A patent/JP6444315B2/ja active Active
-
2015
- 2015-06-15 IL IL239428A patent/IL239428B/en active IP Right Grant
-
2018
- 2018-11-01 CY CY20181101140T patent/CY1122164T1/el unknown
- 2018-11-07 AU AU2018260845A patent/AU2018260845B2/en active Active
- 2018-11-27 JP JP2018221155A patent/JP6772237B2/ja active Active
-
2020
- 2020-09-30 JP JP2020164435A patent/JP2021008483A/ja active Pending
- 2020-11-25 AU AU2020277178A patent/AU2020277178B2/en active Active
-
2021
- 2021-10-01 US US17/491,813 patent/US20220170936A1/en active Pending
-
2022
- 2022-02-28 JP JP2022029441A patent/JP7496380B2/ja active Active
-
2024
- 2024-08-09 AU AU2024205664A patent/AU2024205664A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016511823A5 (https=) | ||
| AU2018260845A1 (en) | Evaluation and treatment of bradykinin-mediated disorders | |
| JP2017524130A5 (https=) | ||
| JP2016536012A5 (https=) | ||
| JP2017500584A5 (https=) | ||
| JP2010516678A5 (https=) | ||
| JP2013500941A5 (https=) | ||
| JP2011177182A5 (https=) | ||
| JP2018511611A5 (https=) | ||
| JP2017505897A5 (https=) | ||
| JP2015513370A5 (https=) | ||
| Jacquemin et al. | The adsorption of dabigatran is as efficient as addition of idarucizumab to neutralize the drug in routine coagulation assays | |
| MY162697A (en) | Methods, devices and kits for detecting or monitoring acute kidney injury | |
| JP2018523105A5 (https=) | ||
| CN103328501A (zh) | 新的生物标记及其在诊断、治疗孤独症中的用途 | |
| JP2019502095A5 (https=) | ||
| NO20074610L (no) | Fremgangsmate for a bestemme mottakeligheten til CHK1 inhibitorer | |
| Mödl et al. | Defects in microvillus crosslinking sensitize to colitis and inflammatory bowel disease | |
| JP2020516289A5 (https=) | ||
| WO2008089135A3 (en) | Identification of biomarkers predictive of dasatinib effects in cancer cells | |
| Farjat-Pasos et al. | Transcatheter patent foramen ovale closure in stroke patients with thrombophilia: current status and future perspectives | |
| EA201491411A1 (ru) | Растворимый manf при поражениях бета-клеток поджелудочной железы | |
| WO2014153232A3 (en) | Methods and compositions for diagnosing preeclampsia | |
| JP2015517463A5 (https=) | ||
| Khattar et al. | Pulmonary hypertension: an unexplored risk factor for stroke in patients with atrial fibrillation |